期刊文献+

子宫肉瘤治疗新进展 被引量:2

原文传递
导出
摘要 子宫肉瘤是一种罕见的恶性肿瘤,在所有子宫恶性肿瘤中占2%~4%。根据其组织来源不同,可分为子宫平滑肌肉瘤(leiomyosarcoma,LMS)、子宫内膜间质肉瘤(endometrial stromal sarcoma,ESS)、子宫恶性中胚叶混合瘤(malignant mixed mesodermaltumor,MMMT)。子宫肉瘤术前诊断困难,易复发、转移,且预后差。
出处 《中国临床研究》 CAS 2015年第6期814-816,共3页 Chinese Journal of Clinical Research
  • 相关文献

参考文献29

  • 1Nam JH. Surgical treatment of uterine sarcoma [ J ]. Best Pract Res Clin Obstet Gynaeco1,2011,25 ( 6 ) : 751 - 760.
  • 2Kapp DS,Shin JY, Chan JK. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas:emphasis on impact of lymph- adenectomy and oophorectomy [ J ]. Cancer, 2008, 112 ( 4 ) : 820 - 830.
  • 3Reed NS, Mangioni C, MalmstriSm H, et al. Phase Ⅲ randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treat- ment of uterinesarcomas stages Ⅰ and Ⅱ : an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study ( protocol 55874 ) [ J ]. Eur J Cancer,2008,44 (6) :808 - 818.
  • 4Omura GA, Blessing JA, Major F, et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study [ J ]. J Clin Oncol, 1985,3 (9) : 1240 - 1245.
  • 5Sutton G, Blessing JA, Malfetano JH. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus : a Gyneco- logic Oncology Group study [ J ]. Gynecol Oncol, 1996,62 (2) :226 - 229.
  • 6Look KY, Sandier A, Blessing JA, et al. Phase Ⅱ trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma:a Gynecolog- ic OncologyGroup (GOG) Study [ J ]. Gynecol Oncol, 2004,92 ( 2 ) : 644 - 647.
  • 7Hensley ML, Blessing JA, Degeest K, et al. Fixed-dose rate gemcit- abine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma:aGynecologic Oncology Group phase Ⅱ study[ J]. Gynecol Oncol,2008,109 ( 3 ) : 323 - 328.
  • 8Hensley ML, Blessing .JA, Mannel R, et al. Fixed-dose rate gemcit- abine plus docetaxel as first-line therapy for metastatic uterine leio- myosarcoma:aGynecologic Oncology Group phase Ⅱ trial [ J ]. Gyne- col Onco1,2008,109 ( 3 ) : 329 - 334.
  • 9Hensley ML,Wathen JK, Maki RG, et at. Adjuvant therapy for high- grade, uterus-limited leiomyosarcoma: results of a phase 2 trial ( SARC 005 ) [ J ]. Cancer,2013,119 ( 8 ) : 1555 - 1561.
  • 10Sanfilippo R, Grosso F, Jones RL, et al. Trabectedin in advanced u- terine lciomyosarcomas:a retrospective case series analysis from two referencecenters [ J ]. Gynecol Oncol,2011,123 ( 3 ) :553 - 556.

同被引文献15

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部